Dataset Information

Autologous multiantigen-targeted T cell therapy for pancreatic ductal adenocarcinoma: results of a Phase I, three-arm, nonrandomized clinical trial (TACTOPS)

ABSTRACT: T-cell therapy has thus far proven ineffective for treating pancreatic ductal adenocarcinoma (PDAC), in part due to heterogeneous expression of tumor-associated antigens (TAAs). In a Phase I/II trial, autologous ex vivo expanded T-cells targeting five TAAs - PRAME, SSX2, MAGEA4, Survivin, and NY-ESO-1 - were prepared and administered (1x107 cells/m2/infusion) monthly to subjects with advanced PDAC responding (Arm A, n=13) or refractory to (Arm B, n=12) first-line chemotherapy, or to those with potentially resectable disease (Arm C, n=12). Primary endpoints were safety and feasibility of delivering 6 infusions; additional endpoints were clinical and immunologic response. Of 56 subjects procured, 37 were infused (median 3 doses), with only one treatment-related serious adverse event reported. Disease control rates in Arms A and B were 84.6% (95% CI: 54.6%-98.1%) and 25% (95% CI: 5.5%-57.2%), respectively; in Arm C, 2/9 resected subjects remain disease-free at 55 and 66 months. The infused cells persisted for up to 12 months post-infusion, and elevated levels of effector, tumor-directed T cells were detected both during dosing (p=0.027) and follow-up in “responders” (objective response in Arms A/B, no relapse in Arm C) compared to “non-responders” (progression in Arms A/B, relapse in Arm C).

ORGANISM(S): Homo sapiens

PROVIDER: GSE307914 | GEO | 2025/09/12

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:Purpose: Decitabine is a deoxycytidine nucleoside derivative inhibitor of DNA-methyltransferases indicated for treatment of myelodysplastic syndrome (MDS). Laboratory evidence shows that pretreatment of AML cell lines can sensitize leukemia cells to chemotherapy and inhibit clonogenic potential. We conducted a randomized study of decitabine when used as priming before standard induction therapy in children with newly diagnosed acute myelogenous leukemia (AML) to evaluate the safety, pharmacokinetics, and any potential early efficacy signal. Exploratory analyses of genomic methylation and RNA expression patterns and minimal residual disease (MRD) were included to elucidate possible biological mechanisms. Methods: This multicenter, randomized, two-arm, open-label study enrolled children ages 1-16 with newly diagnosed de novo AML to either Arm A: daunorubicin, cytarabine, etoposide preceded by a 5-day course of decitabine (experimental arm) or Arm B: daunorubicin, cytarabine, etoposide (control). Following completion of induction therapy, subsequent post-induction treatment was given at the treating physician’s discretion. Patients were monitored for adverse events and samples were collected for PK/PD and biologic analyses. Results: Twenty patients, ages 1-16 years (median 9.4 yrs in both Arms) were treated (10 per Arm). Eighteen of 20 enrolled subjects completed the prescribed treatment. All subjects experienced neutropenia and thrombocytopenia as is expected during AML induction chemotherapy. The most common grade 3 and 4 non-hematologic adverse events observed were caecitis, 2 (20%) subjects in Arm A and 0 (0%) subjects in Arm B; decreased appetite, 3 (30%) subjects in Arm A and 0 (0%) subjects in Arm B; and hypophosphatemia, 2 (20%) subjects in Arm A and 0 (0%) subjects in arm B. One subject in Arm A had appendicitis and colon perforation on Day 6 that led to study discontinuation; the cause was later determined to have been leukemic infiltrate of the bowel wall. Two subjects died (both in Arm A), one of necrotic bowel, pseudomonas sepsis and multisystem organ failure 6 months after study participation and one patient 5 months following study treatment from multisystem organ failure as a complication of stem cell transplant. Plasma concentrations of decitabine showed PK values (mean+SD) of Cmax, 281+113 ng/mL, AUC0-∞, 198+65.3 ng*h/mL, CL, 156+94.6 L/h, Vdss 109+70 L, t1/2 0.48+0.060 h, and median tmax 0.93 h. Overall CR/CRi by morphology was similar between the two treatment arms (92% for the control arm and 100% for the experimental arm). MRD at Day 30 post induction therapy was lower in the control group compared to the decitabine group (67% vs 85% MRD-negative). Changes in DNA epigenetic and RNA expression patterns demonstrated distinct differences involving selective cellular pathways between the two groups of patients comparing diagnostic to day 30 bone marrow samples. Conclusions: This first-in-pediatric trial of epigenetic priming in patients with newly diagnosed AML demonstrates that decitabine pre-treatment followed by standard combination chemotherapy is well tolerated in children with newly diagnosed AML. Morphologic complete responses were similar in both treatment arms. MRD at Day 30 following induction therapy suggests a deeper remission in patients receiving decitabine. No differences were observed between treatment arms in hematologic toxicities although decitabine-treated patients were noted to have more gastrointestinal toxicities, anorexia and hypophosphatemia. Decitabine PK parameters in children were consistent with known adult PK profiles. Molecular changes associated with decitabine pretreatment may be important in the sensitization of clonogenic AML cells. Pre-treatment with decitabine may represent a therapeutic option for use in pediatric AML, when epigenetic modification is a desired focus for treatment.

Dataset Information

Autologous multiantigen-targeted T cell therapy for pancreatic ductal adenocarcinoma: results of a Phase I, three-arm, nonrandomized clinical trial (TACTOPS)

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets